文献速递姑息放疗与转移瘤放疗物理与技术

空间分割放射治疗的高剂量与低剂量:剂量学与临床结局

Highs and Lows of Spatially Fractionated Radiation Therapy: Dosimetry and Clinical Outcomes.
PubMed 文献 · Pract Radiat Oncol · 2024-12-24

单中心回顾性分析2019年10月至2022年6月接受空间分割放射治疗(SFRT)的176例患者共186个治疗部位,最常见剂量为20 Gy单次,88%后续接受全肿瘤放疗至中位EQD2 32.5 Gy。中位随访322天,1年总生存率37%、1年局部控制率81%;SFRT剂量学参数对局部控制有高度预测作用,9例发生3级毒性。

要点

  • SFRT常用方案为20 Gy单次,多数患者后续接受全肿瘤放疗。
  • 1年总生存率37%,1年局部控制率81%。
  • D10%、D90%、等效均匀剂量和平均剂量对局部控制有高度预测作用。

核心结论

  • SFRT是一项有前景的技术,在 bulky 且放射抵抗的异质性肿瘤患者群体中似乎可获得良好的局部控制。
  • SFRT治疗计划的剂量学参数可能是局部控制的独立预测因素。
  • 需要进一步研究以及前瞻性试验来评估SFRT在姑息和根治设置中的作用。

研究设计与样本

  • 单中心回顾性分析,纳入2019年10月至2022年6月接受SFRT的患者,作为机构审查委员会批准的登记和方案的一部分回顾性收集患者特征、肿瘤特征和剂量学参数。
  • 共176例患者、186个治疗部位,中位年龄64岁,最常见组织学为非小细胞肺癌和肉瘤。
  • 采用描述性统计汇总数据,用Kaplan-Meier分析总生存和局部控制,用单变量分析探讨与结局相关的因素。

主要发现

  • 最常见SFRT剂量为20 Gy单次,88%的患者后续接受全肿瘤放疗至中位EQD2剂量32.5 Gy。
  • 中位 gross tumor volume(GTV)为480.5 cc(范围7.8-10,897.8)。
  • 中位随访322天,1年总生存率37%,1年局部控制率81%;局部控制数据可获取于138个治疗部位(131例患者)。
  • SFRT因素包括10%剂量(D10%)、90%剂量(D90%)、等效均匀剂量和平均剂量对局部控制有高度预测作用。
  • 9例患者发生3级毒性,所有这些患者均接受了后续全肿瘤放疗,其中至少2例可归因于意外的肿瘤快速退缩。

局限性

  • 需要进一步研究以及前瞻性试验来评估SFRT在姑息和根治设置中的作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Spatially fractionated radiation therapy (SFRT) intentionally delivers a heterogeneous dose distribution characterized by alternating regions of high and low doses throughout a tumor. This modality may enhance response to subsequent whole tumor radiation in bulky and radioresistant lesions that are historically less responsive to conventional radiation doses alone. The current study presents a single institution experience with modern era SFRT using predominantly a volumetric modulated arc therapy (VMAT) lattice technique. METHODS: Patients treated with SFRT between 10/2019 and 6/2022 were included for analysis. Patient characteristics, tumor characteristics, and dosimetric parameters were collected retrospectively as part of an institutional review board approved registry and protocol. Descriptive statistics were used to collate patient data and Kaplan Meier analysis were generated for overall survival and local control. Univariate analyses were used to investigate factors associated with outcomes. RESULTS: A total of 176 patients with 186 sites treated were included. Median age was 64 and the most commonly treated histologies were non-small cell lung cancer and sarcoma. The most common SFRT dose was 20 Gy in 1 fraction with 88% of patients receiving follow-up whole tumor radiotherapy to a median EQD2 dose of 32.5 Gy (=10). Median gross tumor volume (GTV) was 480.5 cc (7.8-10,897.8). Median follow-up was 322 days with 1 year overall survival 37% and 1 year local control 81%. Local control was available in 138 treated sites (131 patients. SFRT factors including dose to 10% (D10%), dose to 90% (D90%), equivalent uniform dose, and mean dose were highly predictive of local control. Grade 3 toxicity occurred in 9 patients. All of these patients received follow-up whole tumor radiation and at least two of these were attributable to unexpected rapid regression of tumor. CONCLUSIONS: SFRT is a promising technique that appears to confer good local control across a disparate group of patients with bulky and radioresistant tumors. Dosimetric parameters of SFRT treatment plans may be independent predictors of local control. Further investigation is warranted as are prospective trials to evaluate the role of SFRT in both the palliative and definitive setting.

来源:Pract Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Owen D, Harmsen WS, Ahmed SK, et al. Highs and Lows of Spatially Fractionated Radiation Therapy: Dosimetry and Clinical Outcomes. Pract Radiat Oncol. 2024. PMID: 39725127. doi:10.1016/j.prro.2024.12.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。